Drug and medical-device company Abbott Laboratories is scheduled to reports earnings for the third quarter on Wednesday. The following is a summary of key developments and analyst opinion related to the period. OVERVIEW: Late last month Abbott announced it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay, a move that further expands the company's international scope and product portfolio. Abbott highlighted Solvay's access to emerging markets in... Read Full Story
Impax Laboratories Inc. confirmed Friday it is challenging the patents on Abbott Laboratories' cholesterol drug TriCor, and that Abbott is suing Impax for patent infringement. Impax, of Hayward, Calif., said it requested marketing approval for generic versions of 48 milligram and 145 milligram TriCor tablets. Abbott filed suit on Thursday in the U.S. District Court for the District of New Jersey. The lawsuit means the Food and Drug Administration cannot approve Impax's drug for 30 months, or... Read Full Story
The Food and Drug Administration has approved a new test from Abbott Laboratories that detects both types of the virus that causes AIDS. The FDA says the company's Abbott Prism HIV O Plus test can detect HIV types 1 and 2. HIV type 2 is mostly found in West Africa, while HIV type 1 consists of various subgroups found in both the U.S. and West Africa. The test runs on North Chicago, Ill.-based Abbott's Prism system, an automated instrument also used to test blood for hepatitis. The new test... Read Full Story
Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Abbott Laboratories is a dividend aristocrat as well as a component of the S&P 500 index. It has been increasing its dividends for the past 36 consecutive years. Over the past 10 years the company has delivered an average total return of 8.50% annually to its loyal... Read Full Story
Abbott Laboratories says second-quarter profit fell 3 percent, but the drug and medical-device company met Wall Street forecasts as the blockbuster drug Humira continued gaining ground in the market. The company earned $1.29 billion, or 83 cents per share, down from profit of $1.32 billion, or 85 cents per share, during the same period a year prior. Revenue rose 2.5 percent to $7.5 billion from $7.31 billion. Excluding charges, the company said it earned 89 cents per share, while Wall Street... Read Full Story
Ranbaxy Laboratories touched a 52week high of Rs 508. At 2:57 pm, the share was quoting at Rs 506, up Rs 22.35, or 4.62%. It was trading with volumes of 731,974 shares. Yesterday the share closed up 3.10% or Rs 14.55 at Rs 483.65. Read Full Story
2008 was quite an interesting and exciting year for the Healthcare sector. Each sub-sector was struck with their own disruptions and it caused industry wide job cuts and strategic maneuvers. The Obama administration has come in and new legislation will be passed most likely hurting Biotechnology, Pharmaceuticals, and Managed Care. Only time will tell who stands on top after the talks of startling changes quickly dissipates. Nonetheless, I have provided you with three solid choices for your... Read Full Story
By Abt Electronics Abt Electronics is offering an additional 5% off site wide. The sale prices are reflected on the product pages and in the shopping cart online. Some exclusions apply. Offer ends 10-12-09. Go to deal Read Full Story
Abbott Laboratories ABT, manufactures and sells health care products worldwide. The companys Pharmaceutical Products segment offers adult and pediatric pharmaceuticals. began the day at 45.10,ended to 45.00 on volume of 6,775,544 shares. During the day the stock ranged from 44.72 – 45.39 or 67 cents.
Last Trade: 45.00
Day’s Range: 44.72 – [...] Read Full Story
By Abt Electronics Abt Electronics is offering a 20% discount on all AppleCare Protection Plans when you enter the code at checkout for a limited time.
Coupon code: APPLEDAYS
Go to deal Read Full Story
